14 Jan 2022 , 01:35 AM
Alembic Pharmaceuticals announced that it has received tentative approval from the US Food Drug Administration USFDA for its Abbreviated New Drug Application ANDA for Dronedarone Tablets USP 400 mg The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product RLD Multaq Tablets 400 mg of Sanofi-Aventis US LLC SanofiAventis Dronedarone is indicated to reduce the risk of hospitalization for atria fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation Dronedarone Tablets USP 400 mg have an estimated market size of US$ 500 million for twelve months ending September 2021 according to IQVIA Alembic has settled the case with Sanofi-Aventis and will launch its generic as per the terms of settlement
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.